plerixafor has been researched along with liraglutide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abadeh, A; Advani, A; Advani, SL; Connelly, KA; Desjardins, JF; Gilbert, RE; Kabir, G; Mitchell, M; Thai, K; Zhang, Y | 1 |
| Drucker, DJ; Fujishima, H; Fujita, H; Morii, T; Narita, T; Sato, T; Seino, Y; Shimizu, T; Takahashi, T; Takashima, S; Tsukiyama, K; Yamada, Y | 1 |
2 other study(ies) available for plerixafor and liraglutide
| Article | Year |
|---|---|
Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell-derived factor-1α.
Topics: Adamantane; Animals; Benzylamines; Cardiac Catheterization; Chemokine CXCL12; Cyclams; Diabetes Mellitus, Experimental; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Echocardiography; Glucagon-Like Peptide-1 Receptor; Heterocyclic Compounds; Hypoglycemic Agents; Liraglutide; Male; Myocardial Infarction; Rats; Rats, Inbred F344 | 2016 |
Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
Topics: Albuminuria; Animals; Benzylamines; Chemokine CXCL12; Cyclams; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Female; Fibrosis; Glomerular Filtration Rate; Glucagon-Like Peptide-1 Receptor; Heterocyclic Compounds; Humans; Hypoglycemic Agents; Kidney; Linagliptin; Liraglutide; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Receptors, CXCR4; Up-Regulation | 2016 |